MNKD
MannKind CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$791.82M
P/E Ratio
128.50
EPS
$0.02
Beta
1.04
52W High
$6.51
52W Low
$2.23
50-Day MA
$4.00
200-Day MA
$4.72
Dividend Yield
—
Profit Margin
1.68%
Forward P/E
250.00
PEG Ratio
4.39
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | $348.97M |
| Gross Profit (TTM) | $261.01M |
| EBITDA | $58.83M |
| Operating Margin | -6.87% |
| Return on Equity | 0.00% |
| Return on Assets | 4.91% |
| Revenue/Share (TTM) | $1.27 |
| Book Value | $-0.17 |
| Price-to-Book | 187.85 |
| Price-to-Sales (TTM) | 2.27 |
| EV/Revenue | 2.756 |
| EV/EBITDA | 18.67 |
| Quarterly Earnings Growth (YoY) | -34.90% |
| Quarterly Revenue Growth (YoY) | 45.80% |
| Shares Outstanding | $308.10M |
| Float | $302.43M |
| % Insiders | 1.54% |
| % Institutions | 59.70% |
Analyst Ratings
Consensus ($7.50 target)
8
Buy1
HoldData last updated: 4/8/2026